Document is current

Article History

Received: 18 March 2024

Accepted: 14 February 2025

First Online: 19 March 2025

Declarations

:

: The study is being conducted in compliance with the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. The protocol will be approved by each site’s institutional review board. Each study patient must have given written informed consent prior to conducting any study-related procedures.

: Not applicable.

: AO: grant/research support to the University of Pennsylvania from AbbVie, Janssen, Novartis, and Pfizer and to Forward from Amgen and Bristol Myers Squibb; consultant fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, Happify, Janssen, Novartis, Pfizer, and UCB; her husband has received royalties from Novartis. SMR: consultant for, AbbVie, Amgen, Fresnius Kabi, Janssen, Novartis, UCB. SHG: employee University of Pennsylvania School of Medicine). MEH: received consulting fees and/or honoraria from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Sanofi Genzyme/Regeneron and UCB (less than $10,000 each). JUS: consultant for AbbVie, Janssen, Kaleido, Novartis, Pfizer, Sanofi, and UCB; received funding for investigator-initiated studies from Janssen, Novartis, and Pfizer. KSE: None. JK: None. BAL: None. AJSS: receives compensation from the American College of Physicians for editorial work, serves on the External Advisory board for the Florida Atlantic University Summer Institute in Biostatistics, received speaker’s honorarium from NYU in 2023, received consultant fees from WilmerHale on behalf of Gilead Sciences in 2022. SDC: employee of and owns stock in Johnson & Johnson. CG: employee of and owns stock in Johnson & Johnson. JAW: received research funding from AbbVie, Merck, and Pfizer; consulting for AbbVie, Eli Lilly, Janssen, Novartis, and UCB. JRC: received grant/research support from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, UCB, and NIAMS P30AR072583; received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB.